Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication in pulmonary embolism (PE) survivors, characterized by chronic vascular occlusion and pulmonary hypertension. The identification and diagnosis of CTEPH requires a stepwise approach, starting with symptom evaluation, functional evaluation, screening imaging, and progressing to interventional hemodynamic assessment. On the backbone of anticoagulation, CTEPH management necessitates a multidisciplinary approach. Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative option. In nonoperable disease or residual disease after PTE, interventional balloon pulmonary angioplasty and/or pulmonary-vasodilator therapies can be offered, in collaboration with interventional and vascular pulmonary colleagues. As it is a disease that can cause high morbidity and mortality, CTEPH requires a high index of suspicion to diagnose and treat in patients following PE.
Original language | English (US) |
---|---|
Pages (from-to) | 478-484 |
Number of pages | 7 |
Journal | Hematology (United States) |
Volume | 2021 |
Issue number | 1 |
DOIs | |
State | Published - Dec 10 2021 |
Funding
Karlyn A. Martin reports funding from Janssen Scientific Affairs for an investigator-initiated study outside the submitted work. Michael J. Cuttica reports grants and consulting fees from Bayer, United Therapeutics, and Actelion.
ASJC Scopus subject areas
- Hematology